PARMAX · Parmax Pharma Limited · Financials
Market Cap
928.65M INR
Shares
6.88M
Volume · Nov 9
5648
Avg daily vol (3M)
7651
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
121.12M
-57.1%
FY2026
Net Income
-41.59M
-98.6%
FY2026
Operating Cash Flow
-23.55M
-258.9%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 |
|---|---|---|---|
| INR | 183.9M | 121.12M | 282.04M |
| INR | 12.52M | 10.14M | 10.32M |
| INR | 12.41M | 12.4M | 5.86M |
| INR | -28.82M | -58.46M | -23.95M |
| INR | -16.87M | -16.87M | -3.01M |
| INR | -11.95M | -41.59M | -20.94M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.